Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis-Reference-Cited by-同舟云学术

Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis

Published:2023-03 Issue: Volume:39 Page:100573
ISSN:2405-6308
Container-title:Clinical and Translational Radiation Oncology
language:en
Short-container-title:Clinical and Translational Radiation Oncology

Author:

Bodensohn Raphael,Werner Simone,Reis Jonas,Pazos Escudero Montserrat,Kaempfel Anna-Lena,Hadi Indrawati,Forbrig Robert,Manapov Farkhad,Corradini Stefanie,Belka Claus,Theurich Sebastian,Heinzerling Lucie,Schlaak Max,Niyazi Maximilian

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference32 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

2. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N Engl J Med,2015

3. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

4. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial;Hodi;Lancet Oncol,2018

5. Combined Nivolumab and Ipilimumab in melanoma metastatic to the brain;Tawbi;N Engl J Med,2018

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of melanoma brain metastases with radiation and immunotherapy or targeted therapy: A systematic review with meta-analysis;Critical Reviews in Oncology/Hematology;2024-10

2. Multicentric Assessment of Safety and Efficacy of Combinatorial Adjuvant Brain Metastasis Treatment by Intraoperative Radiation Therapy and Immunotherapy;International Journal of Radiation Oncology*Biology*Physics;2024-04

3. Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases;European Journal of Cancer;2023-10

4. Ipilimumab/nivolumab;Reactions Weekly;2023-04-15